Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868381 · ClinicalTrials.gov registry record · Phase 2
A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
A Phase 2 study, sponsored by Stanford University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT06868381: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT06868381 is a Phase 2 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06868381, a Phase 2 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is: \- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT? Participants will: * Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks * Visit the clinic every two to four weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib
Interventions
- DRUG Baricitinib (LY3009104) 4 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06868381
The ClinicalTrials.gov registry entry for NCT06868381 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Baricitinib (LY3009104) 4 mg is the first listed.
NCT06868381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06868381 about?
NCT06868381 is a clinical study titled "A Trial of Baricitinib in Patients With Cardiac Sarcoidosis". The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is: \- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve card...
What is the current status of trial NCT06868381?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2026-04-01. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT06868381?
The interventions under investigation include: Baricitinib (LY3009104) 4 mg (DRUG).
Who is sponsoring clinical trial NCT06868381?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.